Activity of aztreonam-avibactam and ceftazidime-avibactam against β-lactamase-producing enterobacterales Isolates from United States hospitals
New β-lactam/β-lactamase inhibitors were active against common β-lactamase-producing isolates from US hospitals, including carbapenemase-producing isolates for which therapeutic options are limited. Aztreonam-avibactam was the most active agent against carbapenemase producers, including MBL-carrying isolates.
Authors
- Lalitagauri M. Deshpande (ORCID: https://orcid.org/0000-0003-1709-1132)
- Timothy B Doyle (ORCID: https://orcid.org/0000-0002-1083-8742)
- Hélio S. Sader (ORCID: https://orcid.org/0000-0001-7022-6644)
- Mariana Castanheira
Institutions
- JMI Laboratories (US)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2025-06-09
- DOI
- https://doi.org/10.1016/j.jgar.2025.06.002
- Citations
- 3
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- AbbVie